BRAF and melanoma: In the present study, we investigated real-world patient data from stage IV melanoma patients for predictors of particular survival groups, long-term (≥5 years) versus short-term (≤1 year) OS, and examined differences in special patient subgroups by type of first-line therapy and tumor BRAF mutation status.